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Abstract 
 
The present study aimed at identifying the plasma miRNA profile of antiphospholipid 
syndrome patients and to investigate the potential role of specific circulating miRNAs 
as non-invasive disease biomarkers. Ninety antiphospholipid syndrome patients and 42 
healthy donors were recruited. Profiling of miRNAs by PCR-array in plasma of 
antiphospholipid syndrome patients allowed identifying a set of miRNAs differentially 
expressed and collectively involved in clinical features. Logistic Regression and ROC-
curve analyses identified a signature of 10 miRNA ratios as biomarkers of disease. 
Besides, miRNA signature was related to foetal loss, atherosclerosis, and type of 
thrombosis, and correlated with parameters linked to inflammation, thrombosis, and 
autoimmunity. Hard clustering analysis differentiated 3 clusters representing different 
thrombotic risk profile groups. Significant differences between groups for several 
miRNA ratios were found. Moreover, miRNA signature remained stable along time, 
demonstrated by their analysis three months after the first sample collection. Parallel 
analysis in two additional cohorts of patients including either, thrombosis without 
autoimmune disease, and Systemic Lupus Erythematosus without antiphospholipid 
antibodies, displayed each specific miRNA profiles, distinct from those of 
antiphospholipid syndrome patients. In vitro, antiphospholipid antibodies of IgG isotype 
promoted deregulation in selected miRNAs and their potential atherothrombotic protein 
targets in monocytes and endothelial cells. Taken together, differentially expressed 
circulating miRNAs in antiphospholipid syndrome patients, modulated at least partially 
by antiphospholipid antibodies of IgG isotype, might have potential to serve as novel 
biomarkers of disease features and for typifying the atherothrombotic status of patients, 
thus constituting a useful tool in the management of the disease. 
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Abbreviations 
 
aCL, anti-cardiolipin antibodies 
aGAPSS, adjusted global anti-phospholipid syndrome score 
anti-β2GPI, anti-β2-glycoprotein 1 antibodies 
anti-dsDNA, anti-double stranded DNA antibodies 
aPL, antiphospholipid antibodies 
APS, Antiphospholipid syndrome 
AUC, areas under the curve 
CIMT, carotid intima media thickness 
CVD, cardiovascular disease 
Flt-1, VEGF-receptor-1 
HDs, healthy donors 
HUVECs, human umbilical vein endothelial cells 
IPA, Ingenuity Pathway Analysis 
LA, lupus anticoagulant 
MCP-1, Plasmatic levels of monocyte chemotactic protein 
miRNAs, microRNAs 
mRNA, messenger RNA 
PAI-1, plasminogen activator inhibitor-1 
RA, rheumatoid arthritis 
ROC, Receiver-operator characteristics 
SLE, systemic lupus erythematosus 
TF, tissue factor 
VEGF-A, vascular endothelial growth factor A 
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Introduction 
 
The Antiphospholipid syndrome (APS) is a clinical disorder characterized by the 
occurrence of thrombosis and/or pregnancy morbidity associated with the persistent 
presence of antiphospholipid antibodies (aPL), including anti-cardiolipin antibodies 
(aCL), anti-β2-glycoprotein 1 antibodies (anti-β2GPI) and/or lupus anticoagulant (LA).  
Cardiac, cerebral and vascular strokes in these patients are responsible for a 
significant reduction in life expectancy.1 The course of cardiovascular disease (CVD) in 
APS patients may rapidly change from asymptomatic to severe life-threatening 
manifestations difficult to deal with. Timely diagnosis and accurate monitoring of APS 
course are essential to improve the quality of therapy, avoiding approaches based on 
medical empiric protocols. In the same way, as many other autoimmune diseases, APS 
is characterized by a heterogeneous nature that has a dramatic impact on diagnosis 
and treatment.2 
Pathophysiological mechanisms explaining how atherosclerosis and CVD are 
associated to APS have been greatly broadened with the application of genomic 
technologies.3 One emerging and important mechanism controlling gene expression is 
epigenetics, which regulates gene packaging and independent expression of 
alterations in the DNA sequence. Epigenetics, which comprises DNA methylation, 
histone modifications, and microRNAs (miRNAs) activity, is providing new directions 
linking genomics and environmental factors.4 miRNAs are small, non-coding RNAs 
that, depending upon base pairing to messenger RNA (mRNA) mediate mRNA 
cleavage, translational repression or mRNA destabilization. miRNAs are known to be 
involved in crucial cellular processes and their dysregulation has been described in 
many cell types and fluids in a broad range of diseases.5-7 
In the setting of APS, a previous study by our group recognized that aPL modulate the 
expression of 2 miRNAs in monocytes (miR-19b and miR-20a) that control the 
expression of key proteins involved in the pathology of the disease, such as tissue 
factor (TF).8 Moreover, we recently demonstrated that both, aPL and the anti-double 
stranded DNA antibodies (anti-dsDNA) promote specific changes in the expression of 
proteins related to the biogenesis of miRNAs in leukocytes of APS and systemic lupus 
erythematosus (SLE) patients, which are translated in the altered expression of the 
miRNAs profile and that of their protein targets, related to CVD, in these disorders.9 
Extensive analyses have shown that miRNAs are released into the circulation, where 
they are present in concentration levels that differ between healthy subjects and 
patients. Although little is known about the origin and function of such circulating 
miRNAs, these molecules are increasingly recognized as non-invasive and readily 
accessible biomarkers for risk stratification, diagnosis and prognosis of multiple forms 
of CVD.10 
Specific profiles of circulating miRNAs are also associated to the pathophysiology of 
different systemic autoimmune diseases, including SLE, systemic sclerosis, and 
rheumatoid arthritis (RA), and some of them appear to be of diagnostic and possibly 
prognostic value.11 To date, in the context of APS, no study has analysed the potential 
role of the circulating miRNAs as biomarkers of the disease. Therefore, the present 
study was designed to determine the plasma miRNA specific profile of APS patients, 
their modulation by autoantibodies, and their potential role as non-invasive biomarkers 
of disease features. 
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Methods 
Patients 
Ninety patients with primary APS and 42 healthy donors (HDs) were included in this 
study, during a period of 24 months (see Supplemental Material). All experimental 
protocols were approved by the ethics committee of the Reina Sofia Hospital in 
Cordoba (Spain) and written informed consent was obtained. The characteristics of 
patients and HDs are shown in Table 1.  
For each APS patient, the adjusted global anti-phospholipid syndrome score 
(aGAPSS) was calculated as previously described.12 Briefly, aGAPSS was calculated 
by adding the points corresponding to both, the cardiovascular and thrombotic risk 
factors, based on a linear transformation derived from the β regression coefficient as 
follows: 3 for hyperlipidaemia, 1 for arterial hypertension, 5 for aCL IgG/IgM, 4 for anti-
β2GPI IgG/IgM and 4 for LA. 
Two additional cohorts of patients -as disease control-, were further analyzed, including 
23 patients with thrombosis in the absence of an associated autoimmune disease [12 
non-pregnant women and 11 men, mean age 44 (range: 21–73 years), including 
patients with objectively verified thrombotic events: 14 deep venous thrombosis and 9 
thrombosis in intra-cerebral vessels], and 25 SLE patients without aPLs (Supplemental 
Table S1).   
 
Blood sample collection and assessment of biological parameters 
(Supplemental Material).  
 
B-Mode Ultrasound IMT and Ankle Brachial Index measurements 
(Supplemental Material). 
 
Isolation of miRNAs and analysis of miRNAs expression profiling  
Total RNA, including the miRNA fraction, was extracted from both, plasma and 
supernatants obtained from in vitro studies by using the QIAzol miRNeasy kit (Qiagen, 
Valencia, CA, USA) following manufacturer's instructions13 (Supplemental Material). 
To identify the changes that occurred in the expression levels of miRNAs in plasma 
from APS patients and HDs, a Human Serum & Plasma miRNA PCR-array (Qiagen) 
was performed (Supplemental Material) on an exploratory cohort (Supplemental Table 
S2).  
 
Quantitative real-time PCR  
A fixed volume of 3 μl of RNA solution from the 14 μl-eluate from RNA isolation of 200 
μl plasma sample was used as input into the reverse transcription. Input RNA was 
reverse transcribed using the TaqMan miRNA Reverse Transcription kit and miRNA-
specific stem-loop primers (Life Technologies, Madrid, Spain) (Supplemental Material). 
The expression levels of miRNAs were calculated by using 2-Ct and reciprocal ratios 
were performed [Ratio miR-A/miR-B = log2 (2-Ct miR-A/2-Ct miR-B)] as previously    
described.14-19 Reciprocal ratios analysis is an approach that allowed to bypass the 
controversial issue of data normalization of miRNAs in plasma (self-normalization). 
Furthermore, miRNAs whose concentrations are changed due to a pathology in 
opposite directions, can be effective in differentiating investigated populations. 
 
Target gene prediction and integrated analysis by ingenuity pathway analysis 
The altered miRNAs were further analysed to obtain information about biological 
functions, pathways and networks by using the web-based bioinformatics tool 
QIAGEN’s Ingenuity Pathway Analysis (IPA; Ingenuity Systems, 
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http://www.INGENUITY.com). For this purpose, all differentially regulated miRNAs and 
fold changes were imported into IPA.20 (Supplemental Material).  
 
 
Purification of IgG and in vitro exposure of monocytes and endothelial cells to aPL 
antibodies.  
(Supplemental material). 
 
Statistical analysis  
(Supplemental material). 
 
Results 
 
Differentially expressed miRNAs in the plasma of APS patients and HDs 
In the discovery phase (exploratory cohort), we identified 39 miRNAs that were 
differentially expressed between APS patients and HDs (Cut off: 1.7-Fold Change), 
including 19 up-regulated and 20 down-regulated (Figure 1A). 
The functional analysis of the altered miRNAs in APS patients, by using the IPA 
software, showed that a large number of them had validated and putative target 
mRNAs mainly involved in connective tissue disorders, inflammatory response, 
reproductive system disease, CVD or skeletal and muscular disorders (Figure 1B). 
 
Bioinformatic identification and analysis of deregulated miRNAs related to the 
pathophysiology of APS and analysis of potential protein targets 
In-silico studies were performed to identify the altered miRNAs that might have as 
potential targets a number of genes/proteins involved in the development of clinical 
manifestations related to APS, such as coronary artery disease, thrombosis, abortion 
and cerebrovascular dysfunction. Eleven altered miRNAs were identified by IPA as the 
main regulators of proteins involved in the pathology of APS, including miRNA 34a-5p, 
15a-5p, 145a-5p, 133b-3p, 124-3p, 206, 20a-5p, 19b-3p, 210-3p, 296-5p and 374a-5p. 
This set of 11 miRNAs included, among others, the top 5 up-regulated miRNAs and 3 
out of the top 5 down-regulated miRNAs in the PCR-array. The expression levels of the 
11 selected miRNAs were analyzed in all the subjects recruited to the study by RT-
PCR (Figure 1C). MiR-124 and miR-34a were found increased in APS patients in 
relation to healthy donors, while miR-20a, miR-19b and miR145a were found reduced. 
The remaining microRNAs were found also altered, showing a trend to either, increase 
or reduction as observed in the discovery phase, thus validating the data obtained by 
PCR-array.  
 
We further developed a network that defined the interaction miRNA-mRNA targets 
(Figure 2). Key proteins involved in the pathophysiology of APS, and identified as 
potential mRNA targets of those miRNAs, were quantified in the plasma of APS 
patients and HDs. As previously reported,20-23 APS patients showed significantly 
increased plasma levels of TF, PAI-1, MCP-1, VEGF-A and VEGFR-1 (Supplemental 
Figure S1). 
 
Circulating miRNA signature as potential biomarkers of disease in APS 
It has been shown that the combination of miRNAs improves their predictive potential 
to differentiate 2 pathological conditions.14-19 Thus, to asses the potential of specific 
circulating miRNAs in APS patients as biomarkers of disease features, reciprocal ratios 
of the miRNAs analysed were performed by using statistical tools. By this approach, 
we identified 10 miRNA ratios, integrated by the 11 selected miRNAs, and differentially 
expressed in plasma of APS patients in comparison with HDs, including miR-19b/miR-
34a, miR-19b/miR-15a, miR19b/miR-124, miR-19b/miR-145, miR-20a/miR-145, miR-
 7 
20a/miR-374a, miR-20a/miR-210, miR-20a/miR-133b, miR-206/miR-34a and miR-
124/miR-296 (Figure 3A). 
To further explore the efficiency of these biomarkers to identify APS patients, a 
combination of the 10 miRNA ratios as a panel was carried out by using a logistic 
regression on the data set as previously described.24 Thus, all miRNA-ratios were 
integrated in a single model or equation, which provided a single ‘score’ that allowed us 
to perform the ROC-curve analysis and stablish the cut off for prediction. The ROC 
curve for the 10 miRNA ratios signature revealed a marked accuracy, evidenced by an 
AUC of 0.81. At the optimal cut-off value of 0.6, the sensitivity and specificity of the 
combined miRNA panel for APS identification were of 78% and 80%, respectively 
(Figure 3B). 
 
Stability of miRNA expression profile over time in APS 
Plasma from 21 APS patients included in the study was evaluated again three months 
after the first blood sample collection, to analyze the stability of the circulating miRNA 
profile.  
Results demonstrated that miRNA expression in the second sample collection did not 
change in relation to the first analysis (Supplemental Figure S2A). Moreover, the levels 
of miRNA ratios at baseline correlated significantly with the levels of these ratios three 
months later (Supplemental Figure S2B).  Thus, our data support the theory that there 
is a specific circulating miRNA signature in APS, which remains stable along time. 
 
APS patients show a specific miRNA profile different from both, non-autoimmune 
patients with previous thrombotic events, and aPL-negative SLE patients 
To assess the specificity of the miRNA signature found in APS patients and in order to 
analyse whether the altered expression of the circulating miRNAs evaluated was linked 
to their thrombophilic status, an additional disease group, including 23 patients with 
thrombosis in the absence of an associated autoimmune disease was evaluated. In 
these patients, the ratios formed by the expression levels of the 11 selected miRNAs 
were significantly different from those described in APS patients, except for the ratios 
miR-19b/miR-15a and miR-19b/miR-145 which exhibited non-significant differences 
(Figure 4). 
To evaluate if the altered expression of the miRNA signature was a sign of an 
autoimmune status, an additional disease group, including 25 SLE patients negative for 
aPL, was analyzed. In this SLE cohort the ratios produced by the selected circulating 
miRNAs were significantly different from those found in APS patients, except for the 
ratios miR-19b/miR-34a, miR-20a/miR-374a and miR-124/miR-296 which exhibited 
non-significant differences (Figure 4). 
 
Potential influence of standard therapy on the profile of circulating miRNAs in APS 
APS patients were  classified in two groups, based on the treatment received, including 
30 primary APS patients treated with antiplatelet agents and 62 primary APS patients 
treated with anticoagulant drugs. The statistical comparison between patients treated 
with antiplatelet and anticoagulant agents showed no significant differences in miRNA 
signature, except for the ratio miR-20a/374 (Supplemental Figure S3). 
 
Circulating miRNAs are associated with clinical features of APS and show potential as 
biomarkers for the development of atherosclerosis 
The levels of some circulating miRNA ratios that integrate the signature in APS were 
associated with the ocurrence of foetal losses in these patients, including elevated 
levels of miR-19b/miR-124 and miR-20a/miR-374, and reduced levels of miR-124/miR-
296 (Figure 5A). Associations between miRNA ratios and the type of thrombosis 
suffered by APS patients were also identified. Thus, elevated levels of ratios miR-
20a/miR-145 and miR-20a/miR-374 were significantly associated with the ocurrence of 
arterial thrombosis in APS patients (Figure 5B). Furthermore, the ratios composed by 
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miR-19b/miR-124 and miR-124/miR-296 were also found associated with the presence 
of a pathological CIMT in these patients (Figure 5C). To accurately evaluate their 
relevance as biomarkers of early atherosclerosis, we conducted combined ROC 
analyses of these miRNA ratios. The combination of both circulating miRNA ratios as a 
panel showed an evident accuracy, with an AUC of 0.76 at a sensitivity of 67% and 
specificity of 78% from a cut-off value of 0.41 (Figure 5D). 
 
Cluster analysis 
Hard clustering analysis in the APS cohort differentiated 3 clusters representing 
different thrombotic risk profile groups. Clinical and laboratory parameters of each 
cluster are resumed (Figure 6A). Briefly, cluster 1 (50% of the clustered cohort) was 
characterized by lower prevalence of cardiovascular risk factors and aPL multiple 
positivity.  Conversely, cluster 1 shows a higher rate of venous thrombotic event when 
compared to the other clusters. Cluster 2 (17.6% of the clustered cohort) was 
characterized by a higher rate of cardiovascular risk factors, arterial thrombotic events, 
recurrences and a low prevalence of multiple aPL positivity. Cluster 3 (32.4% of the 
clustered cohort) was represented by a higher rate of multiple aPL positivity, arterial 
thrombotic events, and lower rate of cardiovascular risk factors. When evaluating 
different miRNA ratios expression among clusters, we found a statistically significant 
difference between groups for the following miRNA ratios: miR-19b/miR-124 (ANOVA 
P < 0.001), miR-20a/miR-374 (ANOVA P < 0.05), miR-20a/miR-210 (ANOVA P < 
0.001) and miR-124/miR-296 (ANOVA P < 0.05). miRNA ratios expression in the 
different clusters are summarized (Figure 6B). 
When comparing the aGAPSS values among the different clusters, we found a 
significant difference (t-test P = 0.008) between cluster 1 (mean aGAPSS 5.38; SD 
±1.628) and Cluster 2 (mean aGAPSS 8,67; SD ±3.67). Similarly, we found a 
significant difference (t-test P < 0.001) between cluster 1 and cluster 3 (mean aGAPSS 
10.82; SD ±2.316). aGAPSS values stratifying for clusters are represented (Figure 6C). 
 
Circulating miRNAs correlate with clinical and serological parameters in APS 
Correlation studies showed that the levels of some circulating miRNA ratios that 
integrate the signature in APS, were linked with clinical parameters such as the ABI, 
the presence of elevated titers of aPL, particularly aCL and anti-β2GPI antibodies, and 
the erythrocyte sedimentation rate (Supplemental Table S3). Correlation analyses with 
serological markers related to atherothrombosis further showed significant positive 
correlations with the expression levels of various miRNA ratios and with levels of TF, 
PAI-1, VEGF-A, VEGF-R1 and MCP-1 (Supplemental Table S3). Some of these 
correlations were also found among various miRNA ratios in plasma of APS patients. 
 
Antiphospholipid antibodies modulate the expression of both, the circulating miRNAs 
that integrate the signature in APS and their potential protein targets 
The expression of the 11 selected miRNAs was significantly altered in the supernatant 
of HUVECs treated with aPL-IgG in relation to those treated with a non-immune-IgG 
(Figure 7A) except for the miR-124 and miR-206. Accordingly, this treatment promoted 
in HUVECs the secretion of atherothrombotic proteins, such as TF, PAI-1 and VEGF-
R1 (Figure 7B), potential targets of the miRNAs analysed. On the other hand, the 
expression levels of several miRNAs were deregulated in the supernatant of 
monocytes treated with aPL-IgG, including miR-19b, miR-20a, miR-145, miR-210 and 
miR-296 (Figure 7C). Concomitantly, aPL-IgG treatment promoted in monocytes an 
increase in the secretion of TF, PAI-1 and MCP-1 (Figure 7D) 
 
Discussion 
 
The present study identifies, for the first time, a specific signature of circulating miRNAs 
in APS patients that might serve as potential biomarkers of clinical features of this 
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autoimmune disorder. Moreover, this signature could represent a useful tool to typify 
and stratify patients based on their thrombotic status and cardiovascular risk profile 
(Supplemental Figure S4). 
Circulating miRNAs were firstly described in peripheral blood as promising specific 
biomarkers for a wide range of diseases, such as cancer and other inflammatory 
pathologies.25,26 Thereafter, several studies revealed the altered expression of  
numerous miRNAs in plasma, blood cells, and tissues of systemic autoimmune 
condictions, such as RA and SLE, which were directly associated to disease activity, 
making them potential useful biomarkers for clinical features and follow-up.9,26-29 
However, to date, the specific profile of circulating miRNAs in APS patients has not 
been evaluated. In the present study, the profiling of miRNAs by PCR-array in plasma 
of APS patients has allowed to identify a set of miRNAs differentially expressed and 
collectively associated to clinical features of the disease, such as inflammatory 
response, reproductive system disease, and CVD, among others. We further 
developed a model, by using logistic regression, that identified 10 miRNA ratios, 
differentially expressed, that showed great potential as biomarkers of disease of APS 
patients.  
Recent studies support the evidence that a miRNAs signature has a higher diagnostic 
value than individual miRNAs.14-19 The use of ratios is a feasible approach that 
overlooks the controversial question of normalizing plasma levels of miRNAs, given the 
lack of a reliable normalizer for circulating miRNAs. In addition, the establishment of 
these ratios allows the identification of a combination of expression profiles closer to 
reality in vivo in patients, where the interactions between miRNAs and their specific 
potential targets never occur in a unique or individualized way. In fact, it is likely that, in 
some cases, various miRNAs, whose concentrations are shifted in opposite directions 
in a particular pathology, contribute together and specifically to certain clinical profiles. 
The signatures of circulating miRNAs identified in APS patients integrated miRNAs 
previously described to be altered in other autoimmune and CVD. Thus, miR-19b and 
miR-20a have been shown to be essential modulators of TF expression in APS and 
SLE patients,8 so that reduced expression of such miRNAs contributes to the 
overexpression of TF in monocytes, which is directly associated with the occurrence of 
thrombotic events in APS.21 On the other hand, miR-124, found altered in APS, SLE 
and RA patients at both cellular and plasma levels, modulates the overexpression of 
MCP-1, a key chemokine directly involved in CVD associated to these autoimmune 
conditions.30-33 Likewise, miR-133b and miR-145 have been identified as the most 
promising biomarkers of the pathogenesis of CVD. Both miRNAs participate in the 
differentiation of vascular smooth muscle cells. In addition, miR-133b regulates 
angiogenesis and endothelial function, while miR-145 participates in the stabilization of 
atheromatous plaque.34 The miR-34a is highly expressed in endothelial cells and 
elevated circulating levels of this miRNA have been associated to myocardial 
infarction.35 Moreover, the main target of miR-34a is VEGF-A, a key inflammatory 
protein involved in numerous cardiovascular and autoimmune pathologies, including 
APS.23,36 In the same way, miR-374 has been described as regulator of maintenance of 
vascular integrity.37 The remaining miRNAs members of the signature, including miR-
296, miR-210, miR-206 and miRNA-15 have been found altered in severe 
preeclampsia, one of the leading causes of maternal mortality and neonatal morbidity 
worldwide.38-40 Thus, all the processes regulated by these miRNAs seem to orchestrate 
distinct aspects of APS pathogenesis. 
To assess the specificity of the circulating miRNA signature in APS we evaluated the 
miRNA profile in an additional cohort of patients characterized by the presence of 
previous thrombotic events in the absence of an associated autoimmune disease. The 
miRNAs analysis revealed a differential pattern of expression between these 2 cohorts. 
Those results substantiate previous studies that evidenced the presence of a distinct 
miRNA profile in monocytes and neutrophils of thrombotic non-autoimmune patients 
compared to APS patients.9 This fact could reflect a differential mode of regulation and 
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activity of miRNAs in thrombotic patients compared to APS patients, on which the role 
of autoantibodies might be crucial. Moreover, the analysis of a parallel autoimmune 
population –SLE patients- negative for aPL, also identified a miRNA signature distinct 
from that of APS, thus underlying the potential role of aPLs as regulators of 
thrombosis-related miRNAs in APS, and pointing at the presence of a specific miRNA 
profile relative to the pathogenesis of each disease. 
APS patients recruited in this study were mainly treated with anticoagulant and/or 
antiplatelet agents. All of them have been shown to influence the miRNAs expression, 
an epigenetic process that might help to delineate the mechanisms underlying their 
effects.9,41,42 Thus, we evaluated the potential effect of these treatments on the 
circulating miRNA expression profile. No significant differences were observed in our 
cohort of APS patients between those who received antiplatelet and those treated with 
anticoagulant agents, suggesting that the prothrombotic status induced by effects of 
aPLs, and the consequently deregulated miRNAs, were not differentially modulated 
among these drugs. 
In order to understand the clinical relevance of the altered circulating miRNA signature, 
association and correlation studies were perfomed. Altered expression of various 
miRNA ratios was associated with the presence of previous foetal losses. In line with 
these findings, several studies have shown that the misregulation of circulating 
placental miRNAs in maternal blood, might lead to pregnancy complications, thus 
acting as non-invasive diagnostic and prognostic biomarkers for pregnancy 
monitoring.42-44 Association studies further established a significantly increased 
expression of 2 miRNA ratios in APS patients that had suffered arterial thrombosis in 
comparison with those who experienced venous thrombotic events. Interestingly, both 
miRNA ratios were integrated by the miR-20a, previously reported to be the main 
regulator of TF, whose expression levels has been found to be related to the 
development of arterial thrombosis in the setting of APS.8,45 Finally, we identified 2 
miRNA ratios as clinical relevant biomarkers related to early atherosclerosis 
development in APS patients, which were integrated by the miR-19b and miR-124, 
both of them critical players in the expression of proteins related to inflammation and 
thrombosis in APS and SLE.8,9 
Correlation studies revealed that the altered circulating miRNA signature in APS is 
linked to parameters related to increased risk of peripheral artery disease such as the 
ABI. Moreover, correlations between circulating miRNA levels and numerous altered 
parameters related to inflammation and thrombosis were also identified. These 
correlations support the relationship observed in the in-silico study between the 
selected miRNAs and potential target proteins involved in various clinical features of 
APS. The influence of the autoimmunity in the circulating profile of miRNAs in APS was 
also revealed by the significant correlation between high titers of aPL-IgG and the 
altered expression of several miRNAs integrating the signature. These relationships 
further sustain the ones previously identified among the altered profile of miRNAs in 
APS and SLE at cellular level and the autoimmune and inflammatory profile of both 
autoimmune conditions.9 Therefore, our data suggest that the altered plasma profile of 
miRNAs is an important mechanisin that might contribute to the regulation of the pro-
atherothrombotic status of APS patients, on which aPL seem to play a key role. 
Our in vitro studies further confirmed this hypotesis, demonstrating that aPL-IgG 
antibodies promoted a significant deregulation in the expression levels of both, the 
selected miRNAs and their potential protein targets in the supernatant of cultured 
monocytes and HUVECs, the main drivers of the CVD in the setting of APS. These 
results also confirm and complement previous studies which showed the in vitro effects 
of aPL-IgG in the induction of prothrombotic/inflammatory mediators3,31 and the 
modulation of specific cellular miRNAs involved in their modulation.8,9 
Nevertheless, although our data show specific effects of aPL-IgG on the secretion of 
several circulating microRNAs related to CVD, the contribution of other components of 
the vascular and immune system to the altered profile of circulating miRNAs remains to 
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be defined. In addition, since we did not perform a complete plasma human microarray 
analysis, we cannot exclude the complementary role of other circulating miRNAs in the 
physiopathology of APS. 
Interestingly, our analysis supports a clinical role for the use miRNA ratios when 
stratifying patients for their thrombotic risk. While studying the miRNA expression 
profile have offered enlightment in the understanding of APS pathogenesis,9 its clinical 
utility is still on debate. Our data support that specific miRNA signatures could identify 
subgroups of APS patients showing different clinical profiles (in term of site of 
thrombosis and risk of recurrences), potentially paving the way for their use as useful 
biomarkers that will increase specificity and sensitivity of thrombotic risk assessment. 
Altogether, our data suggest that differentially expressed miRNAs in the plasma of APS 
patients, modulated at least partially by aPL-IgG antibodies, might have potential to 
serve as novel biomarkers of disease features and for typifying the atherothrombotic 
status of patients, thus constituting a useful tool in the management of the disease. 
 
Author Contributions 
 
P.R-L, I.A-R, N.B, ML-T, and MC. A-A developed the in vivo assays, performed the 
experiments and solved technical problems. MA.A, MJ.C, E.C-E, MT.H,  J.L-H, and 
MJ.H-V followed up with patients and contributed useful discussion and suggestions. 
C.P-S, C.M, R.G-C, S.S, and C.L-P formed the hypothesis, directed and coordinated 
the project, designed the experiments, analyzed the data, and wrote the manuscript. 
F.V and P.S performed clinical analysis and contributed useful suggestions. Y.J-G, 
M.R, S.S, I.C, performed statistical analysis and discussed results. 
 
Conflict-of-interest disclosure 
  
The authors declare no competing financial interests. 
 
 
References 
 
1. Young SP, Kapoor SR, Viant MR, et al. The impact of inflammation on 
metabolomic profiles in patients with arthritis. Arthritis Rheum. 2013;65(8):2015-
2023. 
2. Palisi A, Grimaldi M, Sabatini P, et al. A serum nuclear magnetic resonance-
based metabolomic signature of antiphospholipid syndrome. J Pharm Biomed 
Anal. 2017;133:90-95. 
3. Perez-Sanchez C, Barbarroja N, Messineo S, et al. Gene profiling reveals 
specific molecular pathways in the pathogenesis of atherosclerosis and 
cardiovascular disease in antiphospholipid syndrome, systemic lupus 
erythematosus and antiphospholipid syndrome with lupus. Ann Rheum Dis. 
2015;74(7):1441-1449. 
4. López-Pedrera C, Pérez-Sánchez C, Ramos-Casals M, Santos-Gonzalez 
M, Rodriguez-Ariza A, Cuadrado MJ. Cardiovascular risk in systemic 
autoimmune diseases: epigenetic mechanisms of immune regulatory functions. 
Clin Dev Immunol. 2012;2012:9746-9748. 
5. Huang Y, Shen XJ, Zou Q, Wang SP, Tang SM, Zhang GZ. Biological functions 
of microRNAs: a review. J Physiol Biochem. 2011;67(1):129-139. 
6. Xiao C, Rajewsky K. MicroRNA control in the immune system: basic principles. 
Cell. 2009;136(1):26-36. 
7. Alevizos I, Illei GG. MicroRNAs as biomarkers in rheumatic diseases. Nat Rev 
Rheumatol. 2010;6(7):391-398. 
8. Teruel R, Pérez-Sánchez C, Corral J, et al. Identification of miRNAs as potential 
modulators of tissue factor expression in patients with systemic lupus 
 12
erythematosus and antiphospholipid syndrome. J Thromb Haemost. 
2011;9(10):1985-1992.  
9. Pérez-Sánchez C, Aguirre MA, Ruiz-Limón P, et al. Atherothrombosis-
associated microRNAs in Antiphospholipid syndrome and Systemic Lupus 
Erythematosus patients. Sci Rep. 2016;6:31375.  
10. Creemers EE, Tijsen AJ, Pinto YM. Circulating microRNAs: novel biomarkers 
and extracellular communicators in cardiovascular disease? Circ 
Res. 2012;110(3):483-495.  
11. Heegaard NHH, Carlsen AL, Skovgaard K, Heegaard PMH. Circulating 
Extracellular microRNA in Systemic Autoimmunity. EXS. 2015;106:171-195.  
12. Sciascia S, Sanna G, Murru V, Roccatello D, Khamashta MA, Bertolaccini ML. 
GAPSS: The global anti-phospholipid syndrome score. Rheumatology (Oxford). 
2015;54(1):134-138. 
13. Castro-Villegas C, Pérez-Sánchez C, Escudero A, et al. Circulating miRNAs as 
potential biomarkers of therapy effectiveness in rheumatoid arthritis patients 
treated with anti-TNFα. Arthritis Res Ther. 2015;17:49. 
14. Boeri M, Verri C, Conte D, et al. MicroRNA signatures in tissues and plasma 
predict develoment and prognosis of computed tomography detected lung 
cancer. Proc Natl Acad Sci U S A. 2011;108(9):3713-3718.  
15. Hennessey PT, Sanford T, Choudhary A, et al. Serum microRNA biomarkers for 
detection of non-samll cell lung cancer. PLoS One. 2012;7(2):e32307. 
16. Sheinerman KS, Tsivinsky VG, Abdullah L, Crawford F, Umansky SR. Plasma 
microRNA biomarkers for detection of mild cognitive impairment: biomarker 
validation study. Aging (Albany NY). 2013;5(12):925-938. 
17. Matthaei H, Wylie D, Lloyd MB, et al. miRNA biomarkers in cyst fluid augment 
the diagnosis and management of pancreatic cysts. Clin Cancer 
Res. 2012;18(17):4713-4724. 
18. Fortunato O, Boeri M, Verri C, et al. Assessment of circulating microRNAs in 
plasma of lung cancer patients. Molecules. 2014;19(3):3038-3054. 
19. Sharova E, Grassi A, Marcer A, et al. A circulating miRNA assay as a first-line 
test for prostate cancer screening. Br J Cancer. 2016;114(12):1362-1366.  
20. Mayburd AL, Martlínez A, Sackett D, et al. Ingenuity network-assisted 
transcription profiling: Identification of a new pharmacologic mechanism for 
MK886. Clin Cancer Res. 2006;12(6):1820-1827. 
21. Cuadrado MJ, López-Pedrera C, Khamashta MA, et al. Thrombosis in primary 
antiphospholipid syndrome: a pivotal role for monocyte tissue factor 
expression. Arthritis Rheum. 1997;40(5):834-841.  
22. López-Pedrera C, Aguirre MA, Buendía P, et al. Differential expression of 
protease activated receptors in monocytes from patients with primary 
Antiphospholipid syndrome. Arthritis Rheum. 2010;62(3):869-877.  
23. Cuadrado MJ, Buendía P, Velasco F, et al. Vascular endothelial growth factor 
expression in monocytes from patients with primary antiphospholipid 
syndrome. J Thromb Haemost. 2006;4(11):2461-2469. 
24. Xiao B, Wang Y, Li W, et al. Plasma microRNA signature as a noninvasive 
biomarker for acute graft-versus-host disease. Blood. 2013;122(19):3365-3375. 
25. Mitchell PS, Parkin RK, Kroh EM, et al. Circulating microRNAs as stable blood-
based markers for cancer detection. Proc Natl Acad Sci U S A. 
2008;105(30):10513-10518. 
26. Chen X, Ba Y, Ma L, et al. Characterization of microRNAs in serum: a novel 
class of biomarkers for diagnosis of cancer and other diseases. Cell Res. 
2008;18(10):997-1006. 
27. Dai Y, Huang YS, Tang M, et al. Microarray analysis of microRNA expression in 
peripheral blood cells of systemic lupus erythematosus patients. Lupus. 
2007;16:939-946.  
28. Rodriguez A, Vigorito E, Clare S, et al. Requirement of bic/microRNA-155 for 
 13
normal immune function. Science. 2007;316(5824):608-611. 
29. Wang J, Chen J, Sen S. MicroRNA as Biomarkers and Diagnostics. J Cell 
Physiol. 2016;231(1):25-30. 
30. Nakamachi Y, Kawano S, Takenokuchi M. MicroRNA-124a is a key regulator of 
proliferation and monocyte chemoattractant protein 1 secretion in fibroblast-like 
synoviocytes from patients with rheumatoid arthritis. Arthritis Rheum. 
2009;60(5):1294-1304. 
31. Pérez-Sánchez C, Ruiz-Limón P, Aguirre MA, et al. Mitochondrial dysfunction in 
antiphospholipid síndrome: implications in the pathogenesis of the disease and 
effects of coenzyme Q10 treatment. Blood. 2012;119(24):5859-5870. 
32. Ruiz-Limón P, Barbarroja N, Pérez-Sánchez C, et al. Atherosclerosis and 
cardiovascular disease in systemic lupus erythematosus: effects of in vivo statin 
treatment. Ann Rheum Dis. 2015;74(7):1450-1458. 
33. Barbarroja N, Pérez-Sanchez C, Ruiz-Limon P, et al. Anticyclic citrullinated 
protein antibodies are implicated in the development of cardiovascular disease 
in rheumatoid arthritis. Arterioscler Thromb Vasc Biol. 2014;34(12):2706-2716. 
34. Navickas R, Gal D, Laucevičius A, Taparauskaitė A, Zdanytė M, Holvoet P. 
Identifying circulating microRNAs as biomarkers of cardiovascular disease: a 
systematic review. Cardiovasc Res. 2016;111(4):322-337. 
35. Huang Y, Qi Y, Du JQ, Zhang DF. MicroRNA-34a regulates cardiac fibrosis 
after myocardial infarction by targeting Smad4. Expert Opin Ther Targets. 
2014;18(12):1355-1365.  
36. Li N, Wang K, Li PF. MicroRNA-34 Family and Its Role in Cardiovascular 
Disease. Crit Rev Eukaryot Gene Expr. 2015;25(4):293-297. 
37. Licholai S, Blaż M, Kapelak B, Sanak M. Unbiased Profile of MicroRNA 
Expression in Ascending Aortic Aneurysm Tissue Appoints Molecular Pathways 
Contributing to the Pathology. Ann Thorac Surg. 2016;102(4):1245-1252 
38. Choi SY, Yun J, Lee OJ, et al. MicroRNA expression profiles in placenta with 
severe preeclampsia using a PNA-based microarray. Placenta. 2013;34(9):799-
804.  
39. Sheikh AM, Small HY, Currie G, Delles C. Systematic Review of Micro-RNA 
Expression in Pre-Eclampsia Identifies a Number of Common Pathways 
Associated with the Disease. PLoS One. 2016;11(8):e0160808. 
40. Akehurst C, Small HY, Sharafetdinova L, et al. Differential expression of 
microRNA-206 and its target genes in preeclampsia. J Hypertens. 
2015;33(10):2068-2074.  
41. Chan ES, Cronstein BN. Methotrexate--how does it really work? Nat Rev 
Rheumatol. 2010;6(3):175-178. 
42. Tsochandaridis M, Nasca L, Toga C, Levy-Mozziconacci A. Circulating 
microRNAs as clinical biomarkers in the predictions of pregnancy 
complications. Biomed Res Int. 2015;2015:294954 . 
43. Zhao Z, Moley KH, and Gronowski AM. Diagnostic potential for miRNAs as 
biomarkers for pregnancy-specific diseases. Clinical Biochemistry. 2013;46(10-
11):953-960. 
44. Wu L, Zhou H, Lin H, et al. Circulating microRNAs are elevated in plasma from 
severe preeclamptic pregnancies. Reproduction. 2012;143(3):389-397. 
45. Tatsumi K, Mackman N. Tissue Factor and Atherothrombosis. J Atheroscler 
Thromb. 2015;22(6):543-549 
 
 
 
 
 
 
 
 14
 
 
 
 
 
 
 
 
 
 
Tables 
 
Table 1. Clinical and laboratory parameters of the APS patients and the healthy 
donors 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
APS indicates the antiphospholipid syndrome; HDs, healty donors; NS, not significant; 
CIMT, carotid intima-media thickness; ABI, ankle brachial index; aPL, antiphospholipid 
antibodies; LA, lupus anticoagulant; aCL, anti-cardiolipin antibodies; GPL, IgG 
phospholipid units; MPL, IgM phospholipid units; anti-β2GPI, anti-β2 glycoprotein 1 
antibodies; SGU, stantard IgG units; SMU, standard IgM units; HDL, high-density 
lipoprotein; LDL, low-density lipoprotein; and ESR, erythrocyte sedimentation rate;  
*Results are expressed in mean ± SD; #Results are expressed in mean and values 
range. †antiplatelet agents include acetylsalicylic acid and Clopidogrel; ‡anticoagulant 
agents indicate vitamin K antagonists, including warfarin and acenocumarol. 
CLINICAL AND LABORATORY  
PARAMETERS 
APS 
(total no. 90) 
HDs 
(total no. 42) P 
 Females/males, no. 48/42 22/20 
 
 Age, years 51.2 ± 13.1 46.2 ± 13.4 NS 
 Arterial thrombosis, no. 35/90 0/42 
 
 Venous thrombosis, no.  55/90 0/42 
 
 Recurrences, no. 37/90 0/42 
 
 Pregnancy morbidity, no. 23/90 0/42 
 
 Pathologic CIMT, no.  24/90 6/42 0.00 
 ABI – left* 1.3 ± 0.11 1.2 ± 0.09 0.02 
 ABI – right* 1.27 ± 0.11 1.2 ± 0.09 0.02 
 LA positivity, no.  85/90 0/42 0.00 
 aCL-IgG,# GPL 23.4 (0.5-448) 1.3 (0.5-5) 0.00 
 aCL-IgM,# MPL 21.8 (0-354) 4.9 (0.8-17) 0.00 
 Anti-β2GPI IgG,# SGU 23.9 (0-361) 1 (1-2) 0.02 
 Anti-β2GPI IgM,# SMU 14.8 (0-289) 1.2 (1-2.6) 0.02 
 Antiplatelet agents,† no. 30/90 0/42 
 
 Anticoagulant agents,‡ no.  62/90 0/42 
 
 Total cholesterol level,* mg/dL 191.7 ± 32.06 190 ± 41.8 NS 
 Cholesterol HDL level,* mg/dL 51.09 ± 12.4 55.4 ± 13.1 NS 
 Cholesterol LDL level,* mg/dL 112.1 ± 33.2 118.4 ± 26.9 NS 
 Triglycerides level,* mg/dL 155.1 ± 163.2 88.3 ± 50.07 NS 
 ESR,* mm/h 13.5 ± 13.6 6.6 ± 4 0.05 
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Figure Legends 
 
Figure 1. APS patients showed a specific circulating miRNAs profile related to 
clinical features of this autoimmune disorder. (A) To identify the changes that 
occurred in the expression levels of microRNAs (miR) in plasma from antiphospholipid 
syndrome vs controls, Human Serum & Plasma miRNA PCR-array (Qiagen) was 
performed in the exploratory cohort. In this profile, the expression levels of 19 miRNAs 
were found up-regulated in antiphospholipid syndrome, while 20 miRNAs were down-
regulated. (B) Ingenuity Pathway Analysis (IPA) uncovered the main enriched 
biological functions and pathways on which these microRNAs are involved. The 
analysis included only the functions and pathways with average IPA score >2 
[indicated as -log (P value)]. (C) Validation of selected miRNAs by RT-PCR in the 
whole cohort of APS patients and Healthy donors. (*) indicates P-value<0.05.  
 
Figure 2. Interaction Network of microRNAs identified potential mRNA targets 
involved in clinical features of APS. By using the tool microRNA Target Filter of 
QIAGEN’s Ingenuity Pathway Analysis (IPA, QIAGEN Redwood City, 
www.qiagen.com/ingenuity), the software generated a network including the selected 
microRNAs (miRNAs or miR) and their mRNA targets, filtered by coronary artery 
disease, thrombosis, abortion and cerebrovascular dysfunction. Only targets 
experimentally observed and predicted with high confidence are shown and related by 
direct interactions with their specific miRNA regulators. 
 
Figure 3. A circulating miRNA signature in APS might have potential value as 
biomarkers of disease. (A) Selected microRNAs (miRNAs or miR) were analysed in 
the whole cohort, including 90 antiphospholipid syndrome (APS) patients and 42 healty 
donors, and reciprocal ratios were performed. Beeswarm plot of each differentially 
expressed miR ratio is shown, along with mean, standard deviation, and p-value. For 
statistical analysis, after normality and equality of variance tests, comparisons were 
made by paired Student t test or alternatively using a nonparametric test (Mann-
Whitney rank sum test) (B) A combination of the 10 miRNA ratios as a panel was 
carried out by using logisitic regression on the data set. ROC curve of miRNA panel 
and cut-off were generated based on the predicted probability (P) for each subject as a 
single score. 
The equation used in our model was: Combined miRNA-ratio panel [Logit(p)] = - 0,64+ 
0,034x(miR-19b/miR-34a) + 1,061x(miR-19b/miR-15a) + 0,248x(miR-19b/miR-124) – 
1,704x(miR-19b/miR-145) + 2,34x(miR-20a/miR-145) – 0,729x(miR-20a/miR-374a) – 
0,624x(miR-20a/miR-210) + 0,088x(miR-20a/miR-133b) + 0,166x(miR-206/miR-34a) + 
0,056x(mir-124/miR-296)”. The area under the curve (AUC), sensitivity and specificity 
are displayed, and a cut-off value with higher specificity was selected.  
 
Figure 4. APS patients show a specific miRNA profile distinct from both, non-
autoimmune patients with previous thrombotic events, and aPL-negative SLE 
patients. Twenty-three thrombotic non-antiphospholipid syndrome patients (non-APS) 
and twenty-five aPL-negative SLE patients were included and the circulating microRNA 
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(miRNA or miR) signature of APS were compared. One-way ANOVA was used for 
statistical coparisons. A Bonferroni correction was applied for multiple testing. p < 0.05 
was considered statistically significant. Beeswarm plot of each differentially expressed 
miRNA ratio is shown along with mean, standard deviation and P value. n.s. indicates 
no significant statistical differences.  
 
 
Figure 5. Circulating miRNAs are related to clinical features of APS and show 
potential as biomarkers for the development of atherosclerosis. Assosiations 
studies of altered circulating microRNA (miRNA or miR) ratios and the occurrence of 
previous foetal loss (A), the type of thrombosis suffered (B) and the presence of a 
pathologic carotid intima-media thickness (CIMT) (C). Beeswarm plot of each miR ratio 
is shown, along with mean, standard deviation, and p-value. (D) A combination as a 
panel of the 2 miRNA ratios associated to the pathologic CIMT was carried out by 
using logistic regression on the data set and receiver-operator characteristics (ROC) 
curve analyses were performed. ROC curve of miRNA panel and cut-off were 
generated based on the predicted probability (P) for each patient as a single score. 
The equation used was: “Combined miRNA-ratio panel [Logit(p)] = 0,599 – 
0,133x(miR-19b/miR-124) + 0,007x(miR-124/miR-296)”. The area under the curve 
(AUC), sensitivity and specificity are displayed, and a cut-off value with higher 
specificity was selected. 
 
Figure 6. Specific miRNA signatures might identify subgroups of APS patients 
showing different thrombotic risk profiles: cluster analysis. (A) Clinical and 
laboratory parameters of the 3 clusters. (B) Comparison of the adjusted global anti-
phospholipid syndrome score (aGAPSS) values among the different clusters. (C) 
Evaluation of different microRNA (miR) ratios expression among clusters. HTA 
indicates arterial hypertension; LA, lupus anticoagulant; aCL, anti-cardiolipin IgG/IgM; 
anti-β2GPI, anti-β2 glycoprotein 1 IgG/IgM.  
 
Figure 7. Antiphospholipid antibodies modulate the expression of both, the 
circulating miRNAs that integrate the signature in APS, and their putative protein 
targets. Human umbilical vein endothelial cells (HUVECs) were treated with 
antiphospholipid antibodies and secreted selected microRNAs (miRNAs) (A) and 
putative target proteins (B) levels were determined in the supernatant. Monocytes were 
also treated with antiphospholipid antibodies and secreted selected miRNAs (C) and 
putative target proteins (D) levels were evaluated in the supernatant of culture. 
Differences were analyzed by means of Student’s t-test. Values are the means and 
SEM of 4 independent experiments performed in triplicate. Statistical significance was 
taken as P < .05. TF indicates tissue factor; PAI-1, plasminogen activator inhibitor-1; 
VEGF-A, vascular endothelial growth factor A; VEGF-R1, VEGF-Receptor-1; MCP-1, 
monocyte chemotactic protein. 
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DETAILED METHODS 
 
Patients 
Ninety patients with primary APS and 42 healthy donors (HDs) were included in this 
study, during a period of 24 months. All experimental protocols were approved by the 
ethics committee of the Reina Sofia Hospital in Cordoba (Spain) and written informed 
consent was obtained. All methods were carried out in accordance with approved 
guidelines. Subjects were selected among patients with stable disease for more than 6 
months, without infections, abortions, thrombosis, or changes in their treatment protocol. 
None of the HDs had a history of autoimmune disease, bleeding disorders, thrombosis, 
or pregnancy losses 
 
Blood sample collection and assessment of biological parameters 
Whole blood from subjects was collected by direct venous puncture either, into tubes 
with ethylenediaminetetraacetic acid as an anticoagulant, or into specific tubes for 
obtaining serum. All the blood was processed for the isolation of plasma -within 4 hours 
of collection- by spinning at 2,000 × g for 10 minutes at room temperature. Then, plasma 
and serum were transferred to a fresh RNase-free tube and stored at −80°C. Plasma 
levels of monocyte chemotactic protein (MCP-1), plasminogen activator inhibitor-1 (PAI-
1), vascular endothelial growth factor A (VEGF-A) and VEGF-receptor-1 (Flt-1), were 
quantified using ProcartaPlex multiplex immunoassay, following the manufacturer’s 
recommendations (AffymetrixeBioscience, Vienna, Austria). Plasma levels of TF were 
determined by ELISA [Human Tissue factor (CD142) ELISA Abcam, Cambridge, MA, 
US]. 
 
B-Mode Ultrasound IMT and Ankle Brachial Index measurements 
B-mode ultrasound imaging of the carotid arteries was performed in patients and HDs 
as described previously1,2 using Toshiba equipment (Aplio platform) equipped with 7- to 
10-MHz broadband linear array transducers. Plaque was defined as a focal structure that 
encroached into the arterial lumen of at least 50% of the surrounding CIMT value or 
demonstrated a thickness more than 1.5 mm as measured from the media-adventicia 
interface to the intima-lumen interface (pathologic CIMT). 
The ankle brachial index (ABI) was measured using a blood pressure cuff and a doppler 
ultrasound sensor. The method used was in accordance with a recent consensus 
statement on measuring the ABI3 . The cuff was applied to both arms and ankles. The 
doppler probe was used to determine systolic blood pressure in both brachial arteries in 
the antecubital fossa, in the right and left posterior tibial arteries and the right and left 
dorsalis pedis arteries. A 12-cm cuff was inflated to 20 mm Hg above the systolic arterial 
pressure and slowly deflated. With an 8 MHz doppler probe (mod MD200) we obtained 
the systolic arterial pressure when the first doppler signal was heard. The ankle brachial 
index for each leg was calculated as the ratio of the higher of the two systolic pressures 
(posterior tibial or dorsalis pedis) in the leg and the higher systolic pressure of either the 
left or right arm.  
 
Isolation of miRNAs  
A total of 200 μl of plasma or supernatant from in vitro studies were thawed on ice and 
lysed in 1 mL QIAzol Lysis Reagent (Qiagen). Samples in QIAzol were incubated at room 
temperature for 5 minutes to inactivate RNases. To adjust for variations in RNA 
extraction and/or copurification of inhibitors, 5 fmol of spike-in control non-human miRNA 
(C. elegans miR-39 miRNA mimic: 5′-UCACCGGGUGUAAAUCAGCUUG-3′) were 
added to the samples after the initial denaturation. The remaining extraction protocol 
was performed according to the manufacturer’s instruction. Total RNA was eluted in 14 
μl of RNase-free water and stored at −80°C. 
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miRNAs Expression Profiling 
In a reverse-transcription reaction using miScript HiSpec Buffer from the miScript II RT 
kit (Qiagen), mature microRNAs (miRNAs) were polyadenylated by poly(A) polymerase 
and subsequently converted into cDNA by reverse transcriptase with oligo-dT priming. 
The formulation of miScript HiSpec Buffer facilitated the selective conversion of mature 
miRNAs into cDNA, while the conversion of long RNAs, such as mRNAs was 
suppressed. As a result, background signals potentially contributed by long RNA were 
non-existent. The cDNA prepared in a reverse-transcription reaction was used as a 
template for real-time PCR analysis using miScript miRNA PCR array (which contains 
miRNA-specific miScript Primer Assays) and the miScript SYBR Green kit, (which 
contains the miScript Universal Primer, reverse primer, and QuantiTect SYBR Green 
PCR Master Mix). To profile the mature miRNA expression, a premix of cDNA, miScript 
Universal Primer, QuantiTect SYBR Green PCR Master MIX, and RNAse-free water, 
was added to a miScript miRNA PCR array. That array was provided in a 96-well plate 
format and included replicates of a miRNA reverse transcription control assay (miRTC) 
and a positive PCR control (PPC). Those were the quality control assays used to 
determine the presence of reverse transcription and real-time PCR inhibitors. 
Raw data were analysed with the data analysis software for miScript miRNA PCR arrays. 
The expression levels of miRNAs were normalized to the mean of spiked-in miRNA Cel-
miR-39 and were calculated using the 2-∆∆Ct method. 
The reaction was conducted in a GeneAmp PCR System 9700 (Life Technologies) at 
16°C for 30 minutes, 42°C for 30 minutes and 85°C for 5 minutes. A preamplification 
step was performed at 95°C for 10 minutes, 20 cycles of 95°C for 15 seconds, and 60°C 
for 4 minutes. Real-time PCR was carried out on a Roche LightCycler 480 (Roche 
Applied Science, Penzberg, Germany) at 95°C for 10 minutes, followed by 40 cycles of 
95°C for 15 seconds and 60°C for 1 minute using the TaqMan microRNA assay along 
with TaqMan Universal PCR Master Mix, No AmpErase UNG (Applied Biosystems, San 
Francisco, CA, USA). 
 
Target gene prediction and integrated analysis by ingenuity pathway analysis 
The altered miRNAs were further analysed to obtain information about biological 
functions, pathways and networks by using the web-based bioinformatics tool QIAGEN’s 
Ingenuity Pathway Analysis (IPA; Ingenuity Systems, http://www.INGENUITY.com). For 
this purpose, all differentially regulated miRNAs and fold changes were imported into 
IPA.4 The right-tailed Fisher’s exact test was used to calculate the p-value determining 
the statistical probability that the association between a set of molecules and a pathway 
or function might be due to chance alone. 
 
 
Purification of IgG and in vitro exposure of monocytes and endothelial cells to aPL 
antibodies  
Total IgG from the pooled sera of 7 APS patients, characterized by high titres of aCL 
and anti-β2GPI antibodies, were purified by protein G-Sepharose high-affinity 
chromatography (MAbTrap kit; Amersham Biosciences) following the manufacturer’s 
recommendations. Anti-β2GPI and IgG-aCL activities of purified IgG were confirmed 
by enzyme-linked immunosorbent assays (QUANTA Lite® ß2GPI-IgG and QUANTA 
Lite® ACA IgG III kits, Inova Diagnostics; San Diego, CA, USA). For in vitro studies, 
monocytes isolated from HDs were incubated with human IgG (500 μg/mL) (Jackson 
InmunoResearch Laboratories, Inc, Newmarket, Suffolk, UK) or purified APS patient-
IgG (500 μg/mL) for 6 hours at 37 °C in RMPI medium without FBS, which could 
contain exogenous miRNAs. Primary human umbilical vein endothelial cells 
(HUVECs) were purchased from Lonza Group Ltd (Basel, Switzerland) and cultured 
in Endothelial Basal Medium (EBM, Lonza, Walkersville, MD USA) supplemented with 
10% fetal bovine serum (FBS, Lonza), 0.1% human epidermal growth factor (hEGF, 
Lonza), 0.1% hydrocortisone (Lonza), 0.1% Gentamicin-Amphotericin-B (GA-1000, 
 4 
Lonza), 0.4% bovine brain extract (BBE, Lonza), and 1% Zell Shield (Minerva Biolabs, 
GmbH, Berlin, Germany) at 37 °C and 5% CO2. Confluent cell monolayers were 
treated for 24 hours at 37 °C with aPL-IgG and control-IgG, as described above in the 
absence of FBS. Four independent experiments –performed in triplicate- were carried 
out on passage 4. Supernatants were collected to evaluate the expression levels of 
the miRNAs and potential target proteins released. 
 
 
Statistical analysis 
All data were expressed as mean ± SD. Statistical analyses were performed with SSPS 
17.0 (SPSS Inc, Chicago, IL, USA). Following normality and equality of variance tests, 
clinical characteristics were compared using paired Student’s t-test or alternatively by a 
non-parametric test (Mann-Whitney rank sum test). Paired samples within the same 
subjects were compared by Wilcoxon signed-rank test. Differences among groups of 
treatments were analysed by repeated measures ANOVA. Correlations were assessed 
by Spearman’s rank correlation. Differences were considered significant at P < 0.05. A 
Bonferroni correction was applied for multiple testing in both, one-way Anova analysis 
and in correlation studies. Receiver-operator characteristics (ROC) curves, plotting the 
true positive rate (sensitivity) versus the false positive rate (1-specificity) at various 
threshold settings, and the areas under the curve (AUC) analysis were used to determine 
the sensitivity, specificity and corresponding cut-off values for each plasma miRNA using 
SPSS. Logistic regression was used to develop composite panels of biomarkers to 
identify signatures that could distinguish APS from control and pathologic CIMT with the 
greatest sensitivity and specificity. ROC analysis and arithmetic mean of level expression 
for miRNA-combined was calculated. P < 0.05 was considered statistically significant. 
Subsequently, in order to stratify APS patients according to their relative thrombotic risk, 
we performed a cluster analysis with hard clustering method. Variables included in the 
cluster analysis were cardiovascular risk factors (dyslipidemia, arterial hypertension, 
smoking, diabetes) and aPL profile (LA, aCL IgG/IgM, anti-β2GPI IgG/IgM). Evaluation 
fields included arterial or venous thrombosis, recurrences and miRNAs ratio profile. One-
way ANOVA and t-test were used to assess significant differences between clusters 
regarding the evaluation fields. 
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SUPPLEMENTAL FIGURES 
 
 
 
Supplemental Figure S1. Protein Levels of potential targets of selected microRNA 
in APS. Differential expression of potential proteins targets of the microRNAs selected 
between antiphospholipid syndrome patients (APS patients) and healthy donors at 
plasma level. Differences were analyzed by means of Student’s t-test. Statistical 
significance was taken as p<0.05. TF indicates tissue factor; PAI-1, plasminogen 
activator inhibitor-1; VEGF-A, vascular endothelial growth factor A; VEGF-R1, VEGF-
Receptor-1; and MCP-1, monocyte chemotactic protein. 
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Supplemental Figure S2. Stability of miRNA expression profile over time in APS 
patients. Levels of miRNA ratios profile among 21 APS patients at baseline and three 
months later. A) Boxes indicate the interval between the 25th and 75th percentiles and 
horizontal bars inside boxes indicate median. Whiskers indicate the interval of data within 
1.5 × interquartile ranges (IQR). Closed circles indicate data points outside 1.5 x IQR. Ns, 
indicates no significant statistical difference. B) Correlation study of miRNA ratios profile 
between time 0 and time 3. r, Spearman’s rank correlation coefficient; p denotes p value 
(calculated probability). 
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Supplemental Figure S3. Evaluation of altered circulating microRNA ratios in APS 
in relation to the treatments received. Comparison of circulating microRNA (miR) ratio 
levels between APS patients taking antiplatelet or anticoagulant agents. Boxes indicate 
the interval between the 25th and 75th percentiles and horizontal bars inside boxes 
indicate median. Whiskers indicate the interval of data within 1.5 × interquartile ranges 
(IQR). Closed circles indicate data points outside 1.5 x IQR. * Statistical significance was 
taken as P < .05. NS indicates no significant statistical difference.  
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Supplemental Figure S4. Flow chart of the study. The total number of subjects 
included in the study were 221. In a first step a circulating miRNA PCR Array was 
performed in the exploratory cohort. Then, 11 altered miRNAs involved in clinical 
features of APS were selected to determine their expression in the whole cohort of APS 
patients and HDs. A signature of 10 miRNA ratios was identified as biomarkers for 
diagnosis, along with the development of atherosclerosis and typifying the thrombotic 
risk in APS patients. This signature was stable over time and distinct from two additional 
disease controls (thrombotic non-APS and aPL-negative SLE). In vitro studies with aPLs 
and in vivo supplementation with ubiquinol modulated the expression of the altered 
miRNA signature in APS. miR, microRNA; APS, antiphospholipid syndrome; HDs, 
healthy donors; SLE, systemic lupus erythematosus; aPLs, antiphospholipid antibodies; 
Qred, ubiquinol. 
TOTAL:		
221	SUBJECTS
10	APS	vs	10	HDs Circulating miRNAPCR-Array
Altered microRNAs involved in	clinical features of	 APS	(Ingeunity Pathway Analysis)
Exploratory
cohort
90	APS	vs	42	HDs
CirculatingmicroRNA signature in	APS
(Biomarkers of	disease)
miR-19b/miR-34a,	 miR-19b/miR-15a,	 miR-19b/miR-124,	 miR19b/miR-145,	
miR-20a/miR-145,	 miR-20a/miR-374a,	 miR-20a/miR-210,	 miR-20a/miR-133b,	
miR-206/miR-34a	 and	miR-124/miR-296
21	APS	analyzed again 3	months
after the first sample collection
microRNA stability
Biomarkers for the development
of	atherosclerosis
miR-19b/miR-124	 and	
miR-124/miR-296
Circulating microRNA modulation
In	vitro:	treatment of	monocytes and	
endothelial cells with aPL antibodies Disease control	
(Additional cohorts)
microRNA signature specificity
25	SLE
aPL negative
23	Thrombotic
Non-APS
miR-15a,	miR-19b,	miR-20a,	miR-34a,	miR-124,	miR-133b,	miR-145,	
miR-206,	miR-210,	miR-296	and	miR-374
RT-PCR
Differentially	 expressed	 miRNAs in	the	plasma	 of	APS	patients,	 modulated	 at	least	partially	 by	aPL-IgG	
antibodies,	 might	 have	potential	 to	 serve	as	novel	 biomarkers	 of	disease	and	 typifying	 the	
atherothrombotic status	 of	APS	patients
Biomarkers for stratifying
thrombotic risk (cluster analysis)
miR-19b/miR-124	 ,	miR-20a/miR-
374,	miR-20a/miR-210	 and	miR-
124/miR-296
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SUPPLEMENTAL TABLES 
 
Supplemental Table S1. Clinical and laboratory parameters of the SLE patients 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SLE indicates the systemic lupus erythematosus; SLEDAI, Systemic Lupus 
Erythematosus Disease Activity Index; CIMT, carotid intima-media thickness; aPL, 
antiphospholipid antibodies; aPL, antiphospholipid antibodies; HDL, high-density 
lipoprotein; and LDL, low-density lipoprotein; *All results are expressed in mean ± SD. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CLINICAL AND LABORATORY  
PARAMETERS 
SLE 
(total no. 25) 
 Females/males, no. 22/3 
 Age, years 36 ± 12 
 SLEDAI 2.4 ± 1.7 
 Thrombosis, no. 2/25 
 Neprhopathy, no.  7/25 
 Obesity, no.  4/25 
 Hypertension, no. 4/25 
 Pathologic CIMT, no.  2/25 
 Anti-ds-DNA positivity, no 11/25 
 aPL positivity, no.  0/25 
 Corticosteroids, no. 4/25 
 Antimalarials, no. 25/25 
 Antiplatelets, no.  11/25 
 Total cholesterol level,* mg/dL 173.1 ± 29.5 
 Cholesterol HDL level,* mg/dL 58.4 ± 26.5 
 Cholesterol LDL level,*	mg/dL 100.4 ± 25.1 
 Triglycerides level,* mg/dL 85.4 ± 32.4 
 C reactive protein,* mg/dL  3.9 ± 6.6 
 C3,* mg/dL 103.8 ± 27 
 C4,* mg/dL 14.9 ± 6 
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Supplemental Table S2. Clinical and laboratory parameters of the exploratory 
cohort 
 
APS indicates the antiphospholipid syndrome; HDs, healty donors; NS, not significant; 
CIMT, carotid intima-media thickness; ABI, ankle brachial index; aPL, antiphospholipid 
antibodies; LA, lupus anticoagulant; aCL, anti-cardiolipin antibodies; GPL, IgG 
phospholipid units; MPL, IgM phospholipid units; anti-β2GPI, anti-β2 glycoprotein 1 
antibodies; SGU, stantard IgG units; HDL, high-density lipoprotein; LDL, low-density 
lipoprotein; and ESR, erythrocyte sedimentation rate;  
*All results are expressed in mean ± SD; #Results are expressed in mean and values 
range. †antiplatelet agents include acetylsalicylic acid and clopidogrel; ‡anticoagulant 
agents indicate vitamin K antagonists, including warfarin and acenocumarol.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 CLINICAL AND LABORATORY   
 PARAMETERS 
APS 
   (total no. 10) 
HDs  
(total no. 10) P 
 Females/males, no.  8/2 7/3  
 Age,* years 49 ± 13 39 ± 7.6 NS 
 Arterial thrombosis, no. 6/10 0/10  
 Venous thrombosis, no.  4/10 0/10  
 Recurrences, no.  5/10 0/10  
 Pregnancy morbidity, no.  4/10 0/10  
 Obesity, no.  2/10 0/10  
 Pathologic CIMT, no.  6/10 0/10  
 LA positivity, no.  7/10 0/10  
 aCL IgG,# GPL 86 (0-462) 1 (0-2) .00 
 aCL IgM,# MPL 41 (0.5-321) 4.1 (0.5-9) .00 
 Anti-β2GPI,# SGU  109.4 (0-387) 2 (0-2.7) .00 
 Antiplatelet agents,† no. 6/10 0/10  
 Anticoagulant agents,‡ no. 4/10 0/10  
 Total cholesterol level,* mg/dL 196 ± 37 197 ± 32 NS 
 Cholesterol HDL level,* mg/dL 54 ± 14 61 ± 9.6 NS 
 Cholesterol LDL level,* mg/dL 123 ± 28 124 ± 27 NS 
 Triglycerides level,* mg/dL 80 ± 28 65 ± 16 NS 
 ESR,* mm/h 13 ± 6 5.1 ± 5 .05 
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Supplemental Table S3. Correlation studies between circulating miRNAs and 
clinical and serological parameters in APS patients 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Spearman´s rank correlations between clinical and serological parameters and miRNA 
ratios showing a p<0,05 are indicated. According to Bonferroni correction a number of 
correlations, indicated in bold, were found significant. ABI indicates ankle brachial index; 
APS, antiphospholipid syndrome; ESR, erythrocyte sedimentation rate; TF, tissue factor; 
PAI-1, plasminogen activator inhibitor-1; VEGF-A, vascular endothelial growth factor A; 
VEGF-R1/Flt-1, vascular endothelial growth factor receptor-1; and MCP-1, monocyte 
chemoattractant protein-1. 
 
 
 
 
 
 
 
 
 
miR 
RATIO 
(miR/miR) 
  CORRELATION    
 COEFFICIENT (r)  
 AND p-VALUE (p) 
CLINICAL PARAMETERS 
ABI-left 20a/374 r= 0.47 p=0.022 20a/210 r= 0.56 p=0.002 
aPL 
20a/374 r= 0.36 p=0.007 
20a/210 r= 0.45 p=0.028 
20a/133b r= 0.43 p=0.001 
20a/145 r= 0.33 p=0.019 
ESR 19b/124 r= 0.35 p=0.031 124/296 r= 0.33 p=0.049 
SEROLOGICAL PARAMETERS 
TF 19b/34a r= 0.33 p=0.042 
20a/133b r= 0.32 p=0.044 
PAI-1 
19b/34a r= 0.29 p=0.048 
19b/15a r= 0.31 p=0.029 
19b/124 r= 0.37 p=0.024 
20a/133b r= 0.35 p=0.006 
VEGF-A 
19b/145 r= 0.39 p=0.038 
19b/34a r= 0.38 p=0.043 
19b/15a r= 0.40 p=0.034 
206/34a r= 0.39 p=0.039 
VEGF-R1/Flt-1 
19b/145 r= 0.43 p=0.006 
19b/34a r= 0.65 p=0.003 
19b/15a r= 0.34 p=0.042 
19b/124 r= 0.38 p=0.029 
20a/145 r= 0.33 p=0.048 
20a/374 r= 0.37 p=0.024 
206/34a r= 0.44 p=0.006 
MCP-1 
19b/34a r= 0.28 p=0.046 
19b/15a r= 0.27 p=0.047 
20a/210 r= 0.34 p=0.006 
